

INDEX

- A2780 human lung carcinoma, 112
A2780 human ovarian cancer, 87
A549 lung carcinoma cells, 6
A82846B, 53
AA1–7, modification of, 52–56
Abacavir (ABC), 325
A β toxicity, 151
Aberrant mitosis, 6
ABJ879, 21–22
AB-ring (biaryl) system, 37
Abscisic acid, 191
Absorption, distribution, metabolism, excretion,
and toxicity (ADMET) data, 358
Acetogenin analogs, synthesis of, 433–434
Acetogenin library, 413
Acetogenin mimics
cytotoxicity of, 430–431, 433
design and synthesis of, 428–437
structural modification of, 432
Acetogenin mimics library, 432–433
parallel fragment assembly strategy for, 434
Acetogenins. *See also* Annonaceous acetogenins
anticancer activities caused by, 400
directional synthetic strategies for, 419
major synthetic emphases related to, 400–401
SAR of, 431–432
bis-THF, 413–422
mono-THF, 401–413
Acetonides, as antiproliferative agents, 16
13-Acetyl-9(*R*)-OH-baccatin III, 89
Acetylcholinesterase inhibitors (AChEIs). *See also*
AChE entries; Anti-AChE potency; Brain
AChE
bivalent, 168
huprines as, 165–166
hybrids of HA with, 162–166
originated from traditional Chinese medicine,
143–144
AChE–HA binding, 167
AChE-inhibitor recognition pattern, 167
“Acid approach,” 92
Acquired immunodeficiency syndrome (AIDS),
325, 357. *See also* HIV entries; Human
immunodeficiency virus (HIV)
Actinoidin-type (type II) glycopeptides, 37, 38
“Active” conformation, 108
Acylation reactions, of eremomycin, 58
3-*O*-Acyl-betulinic acid derivatives, 387
14 β -Acyloxy taxoids, 86
Acyl substitutions, at C-2, 92
Adipic dihydrarzide (ADH), 120
Adolescent students, HA-enhanced memory and
learning performance of, 153
Affinity capillary electrophoresis (ACE), 59
Aglycon glycosylation, 51
Aglycon heptapeptide amino acids, variations and
modifications of, 52–56
Agrimols, 184, 185
Aliphatic acyl groups, 80
Alkenyl linked taxoids, 103
Alkylation reactions, with vancomycin, 57
Alkyl chain, homologation of, 372
12-Alkyl-deoxoartemisinin, 209
Allylic hydroperoxide, 206
Allylic hydroperoxide amino acids, in the pre-
paration of water-soluble taxanes, 117

- Allylic hydroperoxide tubulin, 108
- Altmann, Karl-Heinz, 1
- Alzheimer's disease (AD), 144
- EGb 761 studies related to, 303
- huperzine A in treatment of, 143–172
- Amino acid mutations, paclitaxel resistance and, 116
- Amino acids
- aglycon heptapeptide, 52–56
- aromatic core, 43
- interaction with qinghaosu, 235
- nonproteinogenic, 45
- Amprenavir, 325
- Amycolatopsis balhimycina*, 53
- Analog design, 372
- Anaplastic thyroid carcinoma, 8
- Animals, ZT-1 pharmacokinetics in, 171
- Anluosu, 184, 185
- Annonaceous acetogenins
- activities caused by, 400
- structural characteristics of, 399–400
- Annonacin, total synthesis of, 406–407
- Annadiepoxyde, 196
- Annulide, 189
- A-nor ring, 83
- A-nor-seco baccatin, 85
- A-nor taxoids, 83
- Anti-AChE potency, 165
- Antibiotics. *See* Glycopeptide antibiotics
- Antibody-directed enzyme prodrug therapy (ADEPT) method, 119
- Anticancer activities, caused by acetogenins, 400. *See also* Antitumor activity
- Anticancer agents, 1–2
- Anticancer drugs, Taxol-like, 28
- Anti-HIV-1 activity. *See also* Anti-HIV activity
- of calanolides, 329–331
- of *Calophyllum* coumarins, 329–333
- of cordatolides, 333
- of inophyllums, 331–333
- of 12-*oxo*-(±)-calanolide A, 330
- Anti-HIV-1 agents, most potent, 350–351. *See also* Anti-HIV agents
- Anti-HIV activity. *See also* Anti-HIV-1 activity
- of dibenzocyclooctadiene lignans, 376
- of khellactone derivatives, 360
- of monosubstituted DCK analogs, 363
- Anti-HIV agents. *See also* Anti-HIV-1 agents
- biphenyl derivatives as, 374–379
- chemotherapeutic, 357
- khellactone coumarin analogs as, 358–374
- plant-derived, 357–391
- suksdorfin, 358–359
- triterpene betulinic acid derivatives as, 379–390
- Anti-HIV compounds, 358
- Anti-HIV drugs
- resistance to, 325–326
- search for, 325
- Antimalarial activity. *See also* Malarial entries
- Hansch analysis of, 238
- high-valent iron-oxo-intermediate for, 238
- of qinghaosu, 230–232
- of qinghaosu derivatives and analogs, 221–222
- Antimalarial drugs, immunosuppressive action of, 224
- Antimalarial medicine, Chinese traditional, 184
- Antimicrotubule molecules, paclitaxel-mimicking action of, 122–123
- Anti-p75 MAb MC192, 120
- Antiparasitic activity, of qinghaosu derivatives, 222–223
- Antiproliferative activities, 22, 23
- Antiproliferative agents, 16
- Antiproliferative property, of paclitaxel, 122
- Antituberculosis properties, of (+)-calanolide A, 331
- Antitumor activity. *See also* Anticancer activities
- of BMS-247550, 10
- of Epo B, 8
- of qinghaosu derivatives, 223
- Antitumor agents, 21
- Apoptosis, 6, 121–122. *See also* Cell death
- Aricept, 144
- A ring, 83–85
- A ring substitutions, 81–83
- Aromatic core amino acids, 43
- Arteannuin O, 189–191
- Arteether, microbial transformation of, 202
- Artemether, 183
- degradation reaction with, 230
- microbial transformation of, 202
- oil-soluble, 207
- Artemisia annua*, 183
- essential oils from, 194
- flavonoids and coumarins from, 194–195
- phytochemical studies on, 188
- secondary metabolites of, 197
- terpenoids from, 188–193
- Artemisia annua* components, antitumor activity of, 223
- Artemisia annua* endophytes, components and natural products from, 196–197
- Artemisia apiacea*, 188
- Artemisinic acid, 188
- as the biogenetic intermediate of qinghaosu, 204

- Artemisinin, 183. *See also* Azaartemisinin; Carbaartemisinin; Deoxoartemisinin; Dihydroartemisinin entries; Qinghaosu
- Artemisinin drugs
antimalarial, 221
direct parasitocidal action of, 225
- Artemisinin G, 189
- Artesunate, 183
antitumor effect of, 223
- A-seco ring, 83
- Asimicin
synthesis of, 414
total synthesis of, 420
- Asimilobin, synthesis of, 417–418
- Asiminocin, cytotoxicities against cancer cells by, 416
- Asymmetric total synthesis
of (–)-*trans*-cembranolide, 290
of pseudoplexaurol and 14-deoxycrassin, 284–287
- Atazanavir, 325
- Atropoisomers, 45
- Azaartemisinin, 217
- Aza-calanolide A, 350
- Aza-epothilones, 22–25
- 12-Aza-epothilones, 23
- Azetidine D-ring, 101
- 13 α -Azido baccatin, 82
- m*-Azido baccatin III, 105
- 4-Aziridine analogs, 99
- AZT-resistant strain G910-6, 329
- B16BL6, *in vitro* cytotoxicities against, 406
- Baccatin. *See also* 13 α -Azido baccatin
B-ring rearranged, 91
C-11,12 double bond in, 84
core structure of, 108
- Baccatin III, interaction with tubulin, 107. *See also m*-Azido baccatin III
- Baccatins, 82–83
- Bacteria, Gram-negative and Gram-positive, 39–40
- Bacteria-derived macrolides, 2
- Bacterial isolates, glycopeptide-resistant, 40–42
- Balhimycin, 43, 53
- Bartons protocol, 97
- bcl-2 apoptosis inhibitor, 121–122
- BDFI, 374
- Benzoil taxoids, 87
–lactam approach, 77
–lactam side chains, 75
–tubulin/Epo A complex, 25
–tubulin mutations, 7
- Betulinic acid derivatives. *See also* Bifunctional betulinic acid derivatives
as entry inhibitors, 379–386
as maturation inhibitors, 386–388
30-substituted, 381
- Betulinylamino-undecanoic acid, 380
- Bifunctional betulinic acid derivatives, 389–390
structures and activities of, 390
- Bilobalide, 304
- Bioactive conformations
of epothilones, 25, 26
identification of, 108–110
- Bioactivities, of qinghaosu derivatives and analogs, 221–224. *See also* Biological activity
- Bioactivity-directed fractionation and isolation (BDFI), 358
- Biogenetic synthesis, of qinghaosu, 204–206
- Bioisosteric replacement, 365–366
- Biological activity. *See also* Bioactivities of the natural cembranoids, 266
of sarcophytol A and sarcophytol B, 265–266
- Biological effects, of Epo B, 4–9
- Biological functions, GSH in, 235
- Biomimetic synthesis, 203
- Biomolecules, interaction with carbon-centered free radical, 232–237
- Biosynthesis
ginkgolide, 306–307
glycopeptide, 43–45
qinghaosu, 202–206
- Biosynthesis approaches, combinatorial, 51
- Biosynthesis inhibitors, cell wall, 65
- Biotechnological methods, evaluation of, 52
- Biotransformation, of qinghaosu, 201–202
- Biphenyl compounds, 378
- Biphenyl derivatives, 376–378
as anti-HIV agents, 374–379
mechanism of action of, 378–379
structures of, 377
- Bisnor cadinane sesquiterpene, 191
- BMS-184476, 96
- BMS-247550, 10, 18, 19
clinical trials with, 27
- BMS-310705, 19
semisynthetic derivatives of, 27
- Brain AChE, inhibitory action of huperzine A on, 148
- Brain injury, hypoxic-ischemic, 151
- Breast cancers, drug-resistant, 111. *See also* Breast carcinoma
- Breast carcinoma
LCC6, 103
MCF-7, 112

- B-ring contracted taxoids, synthesis of, 91
 B ring substitutions, 87–94
 Bromoacyl paclitaxel analogs, 119
 Bromobalhimycines, 53
 Bruceines, 184, 185
 Bullalin, total synthesis of, 415
 Bullanin, synthesis of, 414
 Butitaxels, 77
 3'-*t*-Butylaminocarbonyloxy paclitaxel analogs, 80
 Butyrylcholinesterase (BuChE)
 huperzine A inhibition of, 148
 ZT-1 inhibitory activity on, 170
- C-2-acetoxy-C-4-benzoate, 93
 C-2 benzoate, 107
 C-2 debenzoylation method, 92
 C-2 modifications, combined with C-3' modifications, 92–93
 C-2 *m*-substituted benzoyl taxoids, 87
 C-2 *para*-substituted benzamido docetaxel analogs, 94
 C-2 substitutions, 92–94
 C2'-C3' linkage, 81
 C-2' position, substitutions at, 77
 C-3, qinghaosu modification on, 216
 C3'-C4 linked macrocyclic taxoids, 104
 C-3'-difluoromethyl docetaxel analogs, 111
 C3'*N*-C2 linked macrocyclic analogs, 103
 C3'*N*-C2 tethered taxoids, 103
 C3'*N*-debenzoyl *N*-acyl analogs, 112
 C3'*N* modified taxane library, 81
 C3'*N* substitutions, 80–81
 C3'*N*-thiourea bearing paclitaxel analogs, 80
 C-3' position, substitutions at, 77–79
 C3'-*t*-butyl paclitaxel analogs, synthesis of, 80
 C-3'-thiocarbamate paclitaxel analogs, 112
 C-4, qinghaosu modification on, 214–216
 C-4 deacetylation reactions, 99
 C-4 OMe paclitaxel analog, 99
 C-4 substitutions, 99–100
 C5/N4 amide group, 24
 C-6 benzoyl group, 375
 C-6 substitutions, 98–99
 C-7 ester library, 94
 C-7 substitutions, 94–97
 C-9 substitutions, 88–92
 C-10-modified paclitaxel analog library, 87
 C-10 substitutions, 87–88
 C-11, qinghaosu modification on, 214, 217
 C-12, qinghaosu modification on, 214–216, 217
 C12/C13-cyclopropane-based epothilone analogs, 21
 C12/C13-modified epothilone analogs, 15
 C12/C13 *trans*-analog, of epothilones, 16
 C-13, qinghaosu modification on, 216–217
 C-13 ester A-nor-seco analogs, 85
 C-13 keto group, 82
 C-13 linkage, 81–83
 C-13 phenylisoserine derivatives, cytotoxicities of, 91
 C-13 phenylisoserine side chain, conformation of, 110
 C-13 side chain
 incorporation into Taxol, 74–81
 role of, 124
 C16/C17 double bond, 20
 C16-desmethyl-Epo B, 18
 C18-N bond, 20
 C-19 side chain, modification of, 380–381
 C20-desmethyl-C20-methylsulfanyl-Epo B, 28
 C21-amino-Epo B, 19, 28
 C26-fluoro-Epo B, 18
 C-26-modified epothilone analogs, 17–18
 C-28 side-chain betulinic acid derivatives, 383
 Cadinane sesquiterpenes, 189
 Calanolide A, 326
 heterocyclic rings in, 337
 optically active, 340–343
 (+)-Calanolide A, 331
 clinical trial of, 334
 pharmacology of, 333–334
 synthesis of, 346–347, 349
 total synthesis using (–)-quinine catalyzed
 IMA, 343–347
 (–)-Calanolide A, synthesis using catalytic enantioselective approach, 347–349
 (±)-Calanolide A, racemic structural analogs of, 350. *See also* Synthetic (±)-calanolide A
 12-oxo-(±)-Calanolide A, anti-HIV-1 activity of, 330
 Calanolide B, optically active, 340–343
 (+)-Calanolide B, 342
 synthesis of, 347
 (–)-Calanolide B, 331
 synthesis using catalytic enantioselective approach, 347–349
 Calanolides
 activities against HIV-1-specific-inhibitor-resistant viruses, 332
 anti-HIV-1 activity in hollow fiber mouse, 331
 anti-HIV-1 activity of, 329–331
 pharmacology of, 333–334
 structural modification of, 349–350
Calophyllum coumarins
 anti-HIV-1 activity of, 329–333
 preparation of, 334–349

- Camptothecin, 73
- Cancer, as a severe health problem, 1. *See also*
- Anticancer entries; Breast cancer;
 - Colorectal cancer; Human cancer cell lines;
 - Ovarian cancers; Tumor entries
- Cancer cells. *See also* Carcinoma cell lines;
- Epidermoid cancer/carcinoma cell lines;
 - Human cancer cell lines; KB-31 epidermoid cancer/carcinoma cell line; Non-small cell lung cancer (NSCLC) cells
- cytotoxicity of acetogenin mimics toward, 433
- cytotoxic results of mimics toward, 430–431
- drug-resistant, 114
- Capillary electrochromatography, chiral selectors used for, 47
- Capillary electrophoresis, glycopeptides as chiral selectors in, 47–49
- Carbaartemisinin, 218
- Carbamate, introduction to C-10, 111
- Carbohydrate residues, coupling reactions at, 57–58
- Carbonate, introduction to C-10, 111
- Carbon-centered free radicals, 228
- interaction of biomolecules with, 232–237
- Carboxyl group, qinghaosu derivatives containing, 213–214
- Carcinoma cell lines, inhibition by 12-azapothilones, 23
- C-centered radicals, 237
- CCRF-CEM human leukemia cell line, 12, 14
- CCRM-VEM human leukemia cell line, 12
- Cell culture, anti-HIV-1 activity of calanolides in, 329–331
- Cell death, BMS-247550-induced, 10. *See also* Apoptosis
- Cell lines, Epo-resistant, 7. *See also* Cancer cells; Carcinoma cell lines; Human cancer cell lines; Ovarian carcinoma cell line
- Cell poisoning, apoptosis and, 121
- Cell wall biosynthesis inhibitors, 65
- Cembrane diterpenoids, 257
- Cembrane-type constituents, from *Sarcophyton*, 258–265, 260
- Cembrane-type diterpenes, synthetic strategy of, 266–267. *See also* Cembranoid diterpenes
- Cembrane-type diterpenoids, macrocyclization methods of, 291–295
- Cembranoid diterpenes, 260. *See also* Cembrane-type diterpenes
- cytotoxic, 262
 - isolation of, 258
 - from unidentified species, 261–262
- Cembranoid lactones, seven-membered, 264
- Cembranoids
- studies on, 257–295
 - total synthesis of, 266–291
- (±)-*cis*-Cembranolide, synthesis of, 287–289
- (–)-*trans*-Cembranolide, asymmetric total synthesis of, 290
- Cembranolides, total synthesis of, 287–290
- Cembrene A
- synthesis of, 269
 - total synthesis of, 272–276
- (*R*)-Cembrene A, 271
- R*-(–)-Cembrene A
- enantioselective total synthesis of, 273
 - total synthesis of, 274
- (*S*)-Cembrene A, synthesis of, 274
- (–)-3Z-Cembrene A, synthesis of, 273
- Cembrene C, 271–272
- total synthesis of, 276–277
- Cembrenoid epoxides (cembrenoxides), 277
- Cembranoids, natural epoxy, 277–287
- Cephalomannine, 81
- 12-C ethanol of deoxoartemisinin, 211
- C-glycosides, 209–212
- synthesis of, 211
- ChE inhibition, by ZT-1, 170. *See also* Cholinesterase inhibitors (ChEIs)
- Chemotherapeutic anti-HIV agents, 357
- Chinese herbal medicines, 358
- Chinese medicine, books on, 185. *See also* Traditional Chinese medicine (TCM)
- Chiral HPLC, resolution of synthetic (±)-calanolide A by, 349
- Chloroeremomycin, 40
- Chloroeremomycin biosynthesis gene cluster, 43
- Chloroeremomycin derivatives, 57
- Chloroorienticin A, 53
- Chloroquine derivatives, 115
- 3-Chloro-substituted huprines, 165–166
- Cholinesterase activity, effects of huperzine A on, 147–149
- Cholinesterase inhibitors (ChEIs), 148. *See also* ChE inhibition
- Chromanone ring, 336
- Chromatography, glycopeptides as chiral selectors in, 47–49
- Chromene derivatives, from *Artemisia annua*, 196
- Chromene ring, 335–337, 339
- Clinical development, epothilone analogs in, 26
- Clinical trials, of ZT-1, 172
- CNS incidents, ginkgolide protection against, 315
- Coartem, 183, 207
- C-*O*-D- and D-*O*-E-rings (diarylethers), 37
- Cognex, 144

- Cognition enhancer, huperzine A as, 149
- Cognitive enhancement, by ZT-1, 170
- Cold-induced microtubule depolymerization, 4
- “Collapsed” paclitaxel conformations, 109
- Colletotrichum*, chemical constituents of, 197
- Colorectal cancer, phase II trials with Epo B in, 27
- Combinatorial biosynthesis approaches, 51
- Comparative molecular field analysis (COMFA), 80
- Complestatin (type-V) glycopeptides, 37, 38
- Conformational studies, 25–26
- Conformations
- bioactive, 108–110
 - “nonpolar” and “polar,” 108–109
- (+)-Cordatolide A, 339
- anti-HIV activity of, 340
- (±)-Cordatolide A, synthetic procedure of, 340
- Cordatolides, anti-HIV-1 activity of, 333. *See also* Racemic cordatolides
- Corrossolin
- cytotoxicities against B16BL6 by, 406
 - total synthesis of, 404–406
- Corrossolone, total synthesis of, 401, 402
- Costatolide, 340
- Coumarin derivatives, 326
- Coumarins, 326
- from *Artemisia annua*, 195
 - Calophyllum*, 329–333
- Coumarin skeleton
- hydrophilic moieties in, 367
 - modification of, 362–373
 - substituents on, 362–365
- Coupling reactions, C-terminus and N-terminus, 56–58
- C ring, contraction and expansion of, 100–101
- C-ring contracted analogues, formation of, 100
- C ring substitutions, 94–101
- Crassin, translactonization of euniolide to, 285
- Cremophor EL, 117
- Crystal structures
- of bis-hupyrindones, 169
 - of HB/HA-TcAChE complexes, 169
- C-seco analogs, 113
- C-terminally linked dimers, synthesis of, 58
- C-terminus
- coupling reactions at, 56–57
 - derivatization of, 56–57
- Cyclic adenosine monophosphate (cAMP), 90
- Cyclohexanoate analog, 92
- 3'-Cyclopropane, 111
- Cyclopropane analog, 102
- 7,19-Cyclopropane docetaxel analog, contraction of, 101
- 3'-Cyclopropane paclitaxel analogs, synthesis and cytotoxicities of, 79
- Cyclopropanoyl analogs, 99
- Cyclopropylcarbonyl analogs, 99
- Cysteine, interaction with qinghaosu, 235–236
- Cytokinin, from *Artemisia annua*, 196
- Cytotoxic cembranoid diterpenes, 262
- Cytotoxicities
- of acetogenin mimics, 433–434
 - of C-13 phenylisoserine derivatives, 91
 - of 3'-cyclopropane analogs, 79
 - of qinghaosu, 223
 - unexpected, 105
- Cytotoxic tetraterpenes, 264
- D-Ala-D-Ala peptide binding site, modulation of, 65
- D-Ala-D-Ala peptides, binding of, 40, 49, 52, 57
- D-Ala-D-Lac, ester linkage of, 62–64
- Dalbavancin, 64
- DCK analogs. *See also* 3'R,4'R-di-O(-)-camphanoyl-(+)-cis-khellactone (DCK)
- disubstituted, 364–365
 - monosubstituted, 363
 - potency of, 364
 - structures and anti-HIV activities of, 370
- DCK-lactam analogs, 366
- DCK SAR studies, conclusions from, 373
- DCK stereochemical isomers, 359, 360
- DCP analogs, anti-HIV activity of, 372
- DCP derivatives, 369
- substituted, 371
- 4-Deacetoxy D-seco analog, 102
- 10-Deacetyl-7-acyl analogs, tertiary amine-containing, 95–96
- 10-Deacetyl-10-propionyl paclitaxel, 95
- 10-Deacetyl baccatin (10-DAB), 75–76
- 9-keto group in, 106
- 10-Deacetyl paclitaxel, 87
- 2-Debenzoyloxy-2 α -benzamido docetaxel analogs, 112
- Dechloro-glycopeptides, 53
- Deglycosylated glycopeptide derivatives, 51
- Delavirdine, 325
- Dementia, 144
- Deoxoartelinic acid, 213
- Deoxoartemisinin, 12-C ethanol of, 211
- Deoxoqinghaosu, 203. *See also* Deoxyqinghaosu
- 7-Deoxy-6 α -hydroxypaclitaxel, synthesis of, 98–99
- 7-Deoxy-7 β -sulfur taxane analogs, 96
- 7-Deoxy-9-(R)-dihydro paclitaxel analog, 90
- 9-Deoxy analogues, 90–91
- 4-Deoxyannomonatacin, total synthesis of, 402–403
- Deoxyarteannuin B, 191
- 14-Deoxycrassin, asymmetric total synthesis of, 284–287
- DeoxyEpo F, 18
- Deoxyepothilones, molecular structures of, 13

- trans*-(Deoxy)epothilones, biological features of, 16–17
- Deoxygenated derivatives, preparation of, 97
- 2-Deoxygenation, 94
- 10-Deoxygenation, 88
- 4-Deoxygigantecin, total synthesis of, 420–422
- Deoxyisoartemisinin B, 205
- 1-Deoxypaclitaxel analog, synthesis of, 86
- Deoxyqinghaosu, 198, 201–202. *See also* Deoxyqinghaosu
- dEpoB300, 7
- 5-Desamino HA, 168
- Desleucyl-vancomycin, synthesis of chlorobiphenylbenzyl derivatives of, 62
- 20-Desmethyl-20-methylsulfanyl-Epo B, 21
- Deterioration, double-blind trial of HA on, 153
- 2,4-Diacyl paclitaxel analogs, 92
- Diarylethers, 37
- Dibenzocyclooctadiene lignans
- anti-HIV activities of, 376
 - dibromination of, 376
 - SAR conclusions related to, 378
- Dichlorocephalomannine paclitaxel derivatives, 81
- Didanosine (ddI), 325
- trans*-9,10-Didehydro epothilone analogs, 12
- 2-Difluorobenzoyl paclitaxel analog, 112
- Dihydro-artemisinic acid, 188, 202, 203, 204
- Dihydroartemisinin, 207
- ethers and esters of, 208–209
 - selective killing of cancer cells, 223
- Dihydroartemisinin acetate, 211
- Dihydroartemisinin derivatives, 206
- Dihydro-deoxyarteannuin B, 191
- Dihydrodeoxyisoartemisinin B, 205
- Dihydrofuran cembranoid, 262
- 11,12-Dihydro paclitaxel analogs, 83
- Dihydroqinghaosu, 199, 238
- 9(*R*)-Dihydrotaxol ABT-271, synthesis of, 89
- Diketone ester, in the synthesis of qinghaosu, 200–201
- Dimer approaches, to glycopeptide design, 58–59
- Dimer formation, by glycopeptides, 40
- Dimers
- of qinghaosu, 219–221
 - taxoid-epipodophyllotoxin, 104–105
- 4,4'-Dimethoxy-5,6,5',6'-*bis*(methylenedioxy)-2,2'-*bis*(methoxycarbonyl)biphenyl (BBB), 378
- 5,7-Dimethoxy coumarin, synthesis of, 343
- 3'*R*,4'*R*-*di-O*(-)-camphanoyl-(+)-*cis*-khellactone (DCK), 359–360. *See also* DCK entries
- mechanism of action of, 373–374
 - potency of, 361
 - synthesized, 362
 - thio bioisosteres of, 365
- Dipyrano coumarins, 326, 339
- Diterpene toxins, 258
- DJ-927 taxoid, 89, 113
- DNA, interaction of qinghaosu with, 232–235
- DNA pUCIS, cleavage reactions of, 234
- Docetaxel analogs, 112–113
- 14 β -OH, 85–86
 - 9 β -OH, 89
 - with 7 α -F, 96
- Docetaxels, 79
- D-O-E-rings (diarylethers), 37
- Donepezil, 144
- anti-ChE activities of, 149
- Dose-limiting toxicities, of BMS-247550, 27
- ⁷Dpg, modification of, 56
- D ring, 101–103
- Drug research process, 358
- Drug-resistant malarial parasites, 184
- Drug-resistant tumors, 111–114
- Drug-sensitive human tumor models, 8
- DSB (PA-457)
- discovery of, 386–388
 - mechanism of action of, 388–389
- DSB-resistant mutants, 389
- D-seco analogs, 102, 110
- binding of, 109
- D-thia analogs, 102
- E2020, 144
- E,E*-Farnesal, 268
- E,E*-Farnesol, 268
- Efavirenz, 325
- EGb 761 *Ginkgo biloba* extract, 303, 304
- Electron spin resonance (ESR) signal, 227–228
- 11 α -epimers, qinghaosu, 232
 - 11 β -epimers, qinghaosu, 232
- Emtricitabine (ETC), 325
- Endophytic fungi, in *Artemisia annua*, 197
- Energy optimized conformers, 109
- Enfuvirtide, 325
- Enhanced green fluorescent protein (EGFP), 5
- Enterococcal resistance, molecular mechanism of, 42
- Entry inhibitors, betulinic acid derivatives as, 379–386
- Epidermoid cancer/carcinoma cell lines, 14, 15, 20
- inhibition of, 19
- 10-Epi paclitaxel, 87
- Epo B analogs, 19
- Epo B lactam, 28
- Epo-resistant cell lines, 7
- Epothilone 490, antiproliferative activity of, 12

- Epothilone A, 2–3
 semisynthetic derivatives of, 15
 syntheses of, 3
 tubulin-bound conformation of, 25
- trans*-Epothilone A
 scaffold of, 17
 stereoselective synthesis of, 16–17
- Epothilone analogs, 9–25
 C-26-modified, 17–18
 C12/C13-modified, 15
 in clinical development, 26–27
 improved, 28
 in vivo pharmacological properties of, 11–12
 lactam-based, 9–10
 polar, 24
- Epothilone B, 2–3
 biological effects of, 4–9
 clinical trials with, 26–27
 effects in non-small cell lung cancer cells, 6
 in vitro activity of, 4–8
 in vivo antitumor activity of, 8–9
 treatment of human cancer cells with, 5
- Epothilone C, 13
- Epothilone D, 7, 13, 28
 molecular structures of C-26-modified analogs of, 17
 phase I clinical studies with, 27
 reduced antiproliferative activity of, 14
 stability of, 9–10
 toxicity and efficacy of, 14
- Epothilone pharmacophore model, 10–11
- Epothilones, 2
 bioactive conformation of, 12, 25, 26
 C9–C12 region modifications in, 10–13
 C12/C13 *trans*-analogs of, 16
 chemistry and biology of, 1–28
 cyclopropane- and aziridine-based analogs of, 14
 effects on microtubule bundling, 5
 growth inhibitory effect of, 5
 heterocycle modifications in, 19
 modifications in, 22
 oxirane ring system in, 14
 pharmacophore for, 107
 structure activity relationship of, 3–4
 thiazole moiety position in, 25
- Epothilone structure, side-chain modifications in, 18–22
- 3'-Epoxide, 111
- Epoxide moiety, modifications of, 13–17
- 11,12-Epoxy-13-hydroxycembrene A, total synthesis of, 281
- Epoxy-bridged cembranoid diterpene, 261
- 3,4-Epoxycembrene A, total synthesis of, 281
- (+)-3,4-Epoxycembrene A, 279
- (–)-7,8-Epoxycembrene C, 278–279
 total synthesis of, 281
- (+)-11,12-Epoxycembrene C, 278
 total synthesis of, 281
- (+)-11,12-Epoxysarcophytol A, 279–280
 total synthesis of, 281–283
- Erbix, 120
- Eremomycin, 56
 acylation reactions of, 58
- Eremomycin carboxamides, 57
- Ergosterol, 197
- erythro-trans-threo* configuration, 410
- erythro-trans-threo-trans-threo* configuration, 414
- Essential oils, from *Artemisia annua*, 194
- Esters, of dihydroartemisinin, 208
- 7-Esters, bioactivity of, 95
- Ethers, of dihydroartemisinin, 208
- Evans auxiliaries, 45
- Exelon, 144
- “Extended” conformation, 108
- Falciparum malaria, 221–222
- Fang, Qi-Cheng, 73
- Fang, Wei-Shuo, 73
- E,E*-Farnesal, 268
- E,E*-Farnesol, 268
- trans,trans*-Farnesol derivative, 283
- Fe(II), free radical reaction of qinghaosu with, 225–230. *See also* Ferrous ion
- Febrifugine, 185
- Ferrous ion, reaction of qinghaosu with, 225–230.
 See also Fe(II)
- 5-substituted amino-5,6,7,8-tetrahydroquinolinones, 162
- 5-substituted aminomethyl-2(1*H*)-pyridones, 162
- 5-substituted aminoquinolinones, 162
- Flavonoids, from *Artemisia annua*, 194–195
- Fluorescent paclitaxel analog, 107
- Fluorescent probes, 95
- Fluorine atom, 78–79
- Fluorine-probe approach, 109
- Folate-PEG-modified prodrugs, 120
- Fosamprenavir, 325
- 14 β -acyloxy taxoids, 86
- 14 β -hydroxy taxoids, 86
- 14 β substitutions, 85–86
- 14-Nor-A-seco analogs, 85
- Free hydroxyl acylation, 94
- Free radical reactions
 antimalarial activity and, 230–232
 of qinghaosu with Fe(II), 225–230
 products of, 233

- G2/M arrest, 5, 10
GABA_A receptors, 312, 313
Gag protein, 388–389
Galanthamine hydrobromide, 144
Gigantetrocin A, 410
 total synthesis of, 411
Ginkgo biloba, history of, 303
Ginkgo biloba extract, 301–304
Ginkgo biloba levopimaradiene synthase, 307
Ginkgo evaluation of memory (GEM) study, 303
Ginkgolide analogs, 308
Ginkgolide B, 305, 309
 conversion of GC into, 307
 Gly receptors and, 313
Ginkgolide B derivatives, synthesis of, 310–311
Ginkgolide C, 305, 314
Ginkgolide core, stability of, 305
Ginkgolides
 biosynthesis of, 306–307
 chemistry of, 307–308
 effect on peripheral benzodiazepine receptors, 314–315
 effects of, 314–315
 glycine receptors and, 312–314
 isolation of, 301, 304–306
 medicinal chemistry of, 301–315
 methoxy- and ethoxy analogs of, 310
 platelet-activating factor (PAF) receptor and, 301, 308–312
 quantification of, 305–306
 structure of, 304–306
 three-dimensional quantitative SAR study for, 311
Ginkgolides A, B, C, M, and J, 305. *See also* Ginkgolide B; Ginkgolide C
GlcNAc-MurNAc-L-Ala-D-γ-Gln-L-Lys-D-Ala-D-Ala peptide, 40
Gln292Glu mutation, 7
Glutamate toxicity, huperzine A as protection against, 150–151
Glutathione (GSH), in biological functions, 235
7-Glycerolyl carbonate, of paclitaxel, 117
Glycine alkyl chain, elongation of, 381
Glycine receptors, ginkgolides and, 312–314
Glycopeptide aglycones, biotechnological generation of, 54
Glycopeptide antibiotics, 35–36. *See also* Glycopeptide resistance
 classification of, 37–39
 mode of action of, 39–40
 modifications of, 51–58
 physicochemical properties of, 49
 primary antibiotic effect of, 40
 putative gene functions for, 43
 structural modifications of, 49–65
 structure of, 36, 49
Glycopeptide antibiotic subtypes, structures of, 38
Glycopeptide CDP-1, 52, 55
Glycopeptide derivatives
 deglycosylated, 51
 glycosylation of, 51–52
 semisynthetic, 64
Glycopeptide dimers, synthesis of, 58
Glycopeptide-related molecules, design of, 63
Glycopeptide resistance, 40–43
Glycopeptides. *See also* Glycopeptide derivatives;
 Novel glycopeptides
 ability to form dimers, 40
 with antibiotic activity against vancomycin-resistant bacteria, 59–64
 biosynthesis of, 43–45
 broad applicability of, 47–49
 as chiral selectors, 47–49
 derivatization of, 56–57
 structural features of, 37–39
C-Glycosides, 209–212
 synthesis of, 211
N-Glycosides, 209
 antitumor activity of, 223
O-Glycosides, 208
 antitumor activity of, 223
Glycosylation, of glycopeptide derivatives, 51–52
Gomisin G, 374, 375
Gram-negative bacteria, 39–40
Gram-positive bacteria, 39
Growth inhibitory effect, of epothilones, 5
GS-164, 123
GSH–qinghaosu adduct, formation of, 236–237
Guanosine triphosphate (GTP), 4
GuidAge study, 303

bis-(–)-HA, 165
HA analog design, structure-based, 167–169
HA analogs, anti-AChE activities of, 162
(±)-HA analogs, synthetic, 161–162
HA derivatives, anti-ChE activities of, 163
HA hybrid analogs, 162–166
Handbook of Prescriptions for Emergency Treatments, The (Ge Hong), 185, 186
Hansch analysis, of antimalarial activity, 238
HA-simplified analogs, 162, 164
HA skeleton, construction of, 160
(–)-HA-TcAChE complex, 168
Hemart, 237
Heme, interaction with qinghaosu, 237
Hemoglobin, metabolic pathway for degradation of, 235

- Heptapeptides
 characterization of, 43
 synthesis of, 65
 Heteroclitin F, 374
 Heterocycle-bearing side chain, 18
 Hexapeptides, aminoacylation experiments of, 53
 Highly active antiretroviral therapy (HAART), 325
 High-performance liquid chromatography (HPLC), chiral selectors used for, 47
 HIV-1 RT, 331. *See also* Human immunodeficiency virus (HIV); Nucleoside HIV reverse transcriptase (HIV-RT) inhibitors (NRTIs)
 inhibited by (+)-calanolide A, 334
 inhibitory activity against, 333
 HIV-1 RT-associated DNA polymerase activity, 379
 HIV-1 RTMDR1, 371
 HIV-1-specific inhibitors, viruses resistant to, 332
 HIV drugs, FDA-approved, 325
 HIV-RT-associated RNase H activity, 379
 Hollow fiber mouse, anti-HIV-1 activity of calanolides in, 331
 Homochiral hydroxyl enol ether, 290
⁴Hpg, 52, 55
⁵Hpg, 55–56
 Hu, Tai-Shan, 399
 Huang, Hao, 183
 Human cancer cell lines, net growth inhibition of, 6. *See also* Human leukemia cell lines
 Human cancer cells, treatment with Epophilon B, 5
 Human immunodeficiency virus (HIV), 37, 325. *See also* Acquired immunodeficiency syndrome (AIDS); Anti-HIV entries; HIV entries
 Human leukemia cell lines, 12
 Humans, ZT-1 pharmacokinetics in, 171
 Huperziaceae family, 146, 147
Huperzia serrata, 147
 Huperzine A (HA). *See also* HA entries; Racemic HA; ZT-1
 as an acetylcholinesterase inhibitor, 144
 anti-ChE activities of, 149
 clinical trials of, 154
 derivatives from, 162
 detection of, 146
 dimer hybrids of, 165
 discovery of, 145
 effects on cholinesterase activity, 147–149
 effects on learning and memory, 149–150
 effects on miscellaneous targets, 152
 pharmacology of, 147–152
 physical appearance of, 145
 plant resources for, 147
 in protection of neuronal cells, 150–151
 safety and efficacy of, 153
 side effects with, 152–153
 structural biology of, 166–169
 structure activity relationship of, 161–166
 subchronic administration of, 150
 synthesis of, 154–166
 toxicology of, 152
 in treatment of Alzheimer's disease, 143–172
 (–)-Huperzine A, synthesis of optically pure, 157–160
 (±)-Huperzine A
 keto capamate route to, 157
 Pd-catalyzed route to, 157
 synthetic approaches to, 156
 Huperzine B, 165
 Hupridone, dimers of, 168
 Huprines, 165–166
 Huprine X, 168
 Hyaluronic acid (HA), ADH-modified, 120
 7-Hydroxy-5-methoxy-4-phenyl-8-tigloylcoumarin, 343
 19-Hydroxy-10-DAB, 92
 (–)-13-Hydroxy-11,12-epoxyneocembrene, 279
 Hydroxy acid esters, in prodrug synthesis, 117
 (30S)-Hydroxybullatacin, 414
 3-Hydroxymethyl-4-methyl DCK, 367
 2'-Hydroxymethyl docetaxel, preparation of, 78
 2'-Hydroxymethyl paclitaxel analogs
 diastereomers of, 77
 Hydroxyqinghaosu, 202
 14β-Hydroxy taxoids, 86
 Hydrophobic α-bromoacyl prodrugs, 119
 “Hydrophobic collapse” conformation, 109
 “Hydrophobic collapse” hypothesis, 103, 108
 Hydroquinidine (DHQD-R) type ligands, 362
 Hypoxic-ischemic brain injury, huperzine A for treatment of, 151

 IC9564, 385, 386
 Immunostimulating effects, of paclitaxel, 122
 Immunosuppressive activities, of qinghaosu derivatives, 224
 Indinavir, 325
 Inophyllum B, 333
 (+)-Inophyllum B, synthesis of, 343, 346
 Inophyllum C, 333
 (+)-Inophyllum D, 333
 Inophyllum E, 333
 Inophyllum P, 333
 (+)-Inophyllum P, synthesis of, 343
 Inophyllums, anti-HIV-1 activity of, 331–333. *See also* Racemic inophyllum
 Integrase khellactones, 358–359
 Intramolecular Pd-catalyzed cross-coupling methodology, 293
 In vitro activity, of Epo B, 4–8

- In vitro tubulin polymerization, 23
In vivo antitumor activity, of EpoB, 8–9
Iodolactonization, 202–203
Isoannulide, 189
Isocembrene, isolation of, 295
(±)-Isocembrene
 Stille cyclization approach to, 291–295
 total synthesis of, 295
Iso-ginkgolide derivatives, 308
Iso-paclitaxel, 93
Isotopic-labeled qinghaosu, 206
- Jimenezin, synthesis of, 427–428
- KB-31/C5, 7
KB-31 epidermoid cancer/carcinoma cell line, 10,
 14, 15, 20
KB-31/KB-8511 cell line pair, 24
KB-8511 epidermoid cancer cell line, 10, 15
Khellactone 3'R,4'R-substitutions, 362
Khellactone coumarin analogs, as anti-HIV agents,
 358–374
Khellactone derivatives, 359
 anti-HIV activities of, 360
 cis-Khellactone derivatives, modification of, 361
 trans-Khellactone derivatives, modification of,
 361
Khelthiolactone analogs, 365
 structures and anti-HIV activities of, 366
- Lactam-based epothilone analogs, 9–10
Lamivudine (3TC), 325
LCC6 human breast carcinoma, 103
Learning, effects of huperzine A on, 149–150
Lee, Kuo-Hsiung, 357
Leucine cluster, 116
Leukemia, xenograft models of, 8
Leukemia cell line, 14
Leukemia U937 cell, 95
LH15, 389
LH55, 389, 390
Li, Yi-Ming, 143
Li, Ying, 183
Li, Yulin, 257
Liang, Xiao-Tian, 73
Ligand-AChE complexes, structures of, 167–168
Ligand-tubulin model, 107
Linezolid, 65
Lipophilic residues, attachment of, 64
Lithium dimethylcuprate, addition to conjugated
 cycloalkynone, 289–290
Liu, Gang, 314–315
Longifolicin, total synthesis of, 407–408
Long-term potentiation (LTP), modulation of, 309
Lopinavir, 325
LPS-mimetic factors, 122
Luche reduction, 339
Lung carcinoma
 A2780, 112
 Taxol-resistant, 12
Lung carcinoma cells, 6
Lung tumors, NCI H-460 large cell, 21–22
Lupane, 379, 380
LY264826 derivatives, 57
LY-333328, 58, 59, 64
 structures of, 61
Lycopodiaceae family, 146, 147
Lycopodium alkaloids, 145
Lys-D-Ala-D-Ala peptide, 59
 binding of vancomycin to, 41
- Ma, Tao, 325
MAB-paclitaxel conjugate, 120
Macrocyclic analogs, 103–104
Macrocyclic ring, closure of, 269, 272
Macrocyclic skeleton, macrocyclization method
 for constructing, 291–293
Macrocyclic taxoids, 103
 for drug-resistant cancer cells, 114
Macrocyclization, in the cembranoid field, 266
Macrocyclization methods, of cembrane-type
 diterpenoids, 291–295
Macrolactam ring, 9
Malaria, chloroquine-resistant, 225. *See also*
 Antimalarial entries
Malarial calcium-dependent ATPase (PfATP6),
 237
Malarial parasites, drug-resistant, 184
Maturation inhibitors (MIs), 389
 betulinic acid derivatives as, 386–388
Mavelonic acid lactone (MVA), qinghaosu synth-
 esis from, 204
MCF-7 human breast carcinoma, 112
McMurry coupling, 281
McMurry olefination strategy, 268–269
MDR reversal activities, nonpaclitaxel-type
 taxoids with, 114–115. *See also* Multidrug
 resistance (MDR)
MDR reversal agents, 115
MDR tumors
 paclitaxel analog efficacy against, 111
 P-gP overexpressing, 113
 structure-modified taxoid activity toward,
 111–114
2'-Me analog, Taxol, 77
Membrane-bound receptors, in the CNS, 312
Memory, effects of huperzine A on, 149–150
Memory deficits, effects of ZT-1, HA, and
 donepezil on, 170
Memory study, ginkgo-related, 303

- 2'-(*S*)-Me paclitaxel analogs, 112
meta-substitution, 92
 Methicillin-resistant *Staphylococcus aureus* (MRSA) strains, vancomycin-resistant, 35
cis-(+)-Methoxy chromanone coumarin, 346
 5-Methoxy DCK, 362
 3-Methoxy DCK analogs, 362
 4-Methoxy DCK analogs, 362
 Methoxycarbonyl analogs, 99
 7-Methoxymethyl (MOM) ether, 88
 4-Methyl-5-methoxy DCK, 364
 Methyl-11,12,15-trihydroxy-13(14)-octadecanoate, 196
 Methylcarbonate analogs, 99
 Methylchlorosarcophytoate, 264
 4-Methyl DCK, anti-HIV potency of, 364
 5-Methyl DCK, anti-HIV potency of, 364
 4-Methyl DCK lactam analogs, 367
 Methylenedioxy groups, 375
 Methylisosartouate, 264
 Methylneosartouate, 264
 Methylsarcoate, 262, 264
 Methylsarcophytotate, 264
 7-Methylthiomethyl (MTM) ether, 96
 Microbial transformation, 201
 of artemether and arteether, 202
 Microphysiometry assay, 312
 Microtubule-associated proteins (MAPs), 4
 Microtubule associating protein 4 (MAP4), 116
 Microtubule binding site, paclitaxel and epothilone positioning within, 25
 Microtubule bundling, 5
 in peripheral blood monocytes, 27
 Microtubule depolymerization inhibitors, Epo A and B as, 28
 Microtubule dynamics, suppression of, 6
 Microtubule dynamics alterations, paclitaxel resistance and, 116
 Microtubule inhibitors, improved, 1–28
 Microtubule-interacting agents, classes of, 1–2
 Microtubule polymerization-depolymerization equilibrium, 74
 Microtubules
 binding site of paclitaxel on, 107–108
 spindle, 5
 Microtubule stabilization, 4–5
 “Microtubule stabilizers,” 2
 Microtubule-stabilizing agents, cellular response to, 7
 Microtubule stabilizing effects, 123
 Microtubule structure, improved resolution of, 108
 Mimetics, vancomycin, 62
 Mini-Mental State Examination (MMSE), 153
 “Mini-receptor” model, 108–109
 Mitosis, aberrant, 6
 MOM ethers, 96
 Mono-hydrophobic ester substitution, taxoids with, 114
 Monosubstituted DCK analogs, structures and anti-HIV activities of, 363
 Mosin B, total synthesis of, 410–412
 MT-4 cell line, HIV-1 RTMDR1 in, 368–369
 Mucocin
 chiron approach to, 423–424
 shortest route to, 424–425
 total synthesis of, 422–425, 425–427
 Multidrug resistance (MDR), taxoids overcoming, 11–116. *See also* MDR entries
 Multimer approaches, to glycopeptide design, 58–59
 Muricatetrocin, C-12 epimers of, 408
 Muricatetrocin A, 408–409
 Muricatetrocin B, 409
 Muricatetrocin C, 409–410
 Murisolin, absolute configuration of, 413
 Mutasynthesis, 50–51
 Myasthenia gravis, 153
Mycobacterium tuberculosis (TB), 331
 National Cancer Institute (NCI), Taxol discovery at, 74. *See also* NCI H-460 large cell lung tumors
 N-atom, ring position of, 20
 Natural cembranoids
 studies on, 257–295
 total synthesis of, 266–291
 Natural epoxy cembranoids, total synthesis of, 277–287
 Naturally occurring dibenzocyclooctadiene lignans, SAR analysis of, 374–375
 Natural products, from *Artemisia annua* endophytes, 196–197
 Natural taxoids, multidrug resistance and, 111–116
 NCI H-460 large cell lung tumors, 21–22. *See also* National Cancer Institute (NCI)
 Nelfinavir, 325
 Nephthenol, synthesis of, 269
R-(–)-Nephthenol, enantioselective total synthesis of, 273
 Nerve gas poisoning, huperzine A as a prophylactic drug against, 150
 Neuronal cells, protection by huperzine A, 150–151
 Nevirapine, 325, 379
N-glycosides, 209
 antitumor activity of, 223

- 9 β -dihydro-paclitaxel analogs, 113
9 β -OH-dihydro-paclitaxels, 89
NMR analysis of molecular flexibility in solution (NAMFIS) techniques, 109. *See also* Nuclear magnetic resonance (NMR) methods
Nonadjacent *bis*-THF acetogenins, 420–422
Nonmevalonate pathway, of ginkgolides, 306
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), 325, 331, 369
Nonpaclitaxel-type taxoids, with MDR reversal activities, 114–115
“Nonpolar” conformation, 108–109
Non-prodrug water-soluble paclitaxel analogs, 119
Nonproteinogenic amino acids, syntheses of, 45
Nonribosomal peptide synthetases (NRPS), 43
Non-small cell lung cancer (NSCLC) cells, effects of Epo B in, 6
Nontaxoid MDR reversal compounds, 115
Norannuic acid, 189
(+)-Nortaylorione, 191
Novel glycopeptides, rational concepts for the design of, 58–64
N-terminus
 coupling reactions at, 57–58
 derivatization of, 57–58
Nuclear magnetic resonance (NMR) methods, 36–37. *See also* NMR analysis of molecular flexibility in solution (NAMFIS) techniques
Nucleoside HIV reverse transcriptase (HIV-RT) inhibitors (NRTIs), 325
Nucleotide RT inhibitor (NtRRTI), 325
Nude mouse human tumor models, 9

O-glycosides, 208
 antitumor activity of, 223
Olefinic double bond, transoid arrangement of, 26
1 β substitutions, 85–86
“Open” conformer subfamily, 109
Optically active calanolide A, synthesis of, 340–343
Optically active calanolide B, synthesis of, 340–343
Optically active *Calophyllum* coumarins, preparation of, 340–349
Optically pure (–)-HA, synthesis of, 157–160
Orienticin A, 53
Oritavancin, 59, 64
 structures of, 61
ortho-position linked taxoids, C-4 and C3'-Ph, 104
ortho-substituents, 92
Ovarian cancers
 A2780, 87
 drug-resistant, 111
 Ovarian carcinoma cell line, inhibition of, 21
 Oxetane D ring, role of, 101–102, 110
 Oxidative stress, huperzine A as protection against, 151
 Oxirane ring system, 14
 12-Oxo-(±)-calanolide A, anti-HIV-1 activity of, 330
 “Oxyanion” hole, 169

P388, 73
P450-dependent monooxygenases, side-chain cyclization reactions performed by, 44
PA-457, discovery of, 386–388
Paclitaxel, 2, 5–6, 73. *See also* Iso-paclitaxel; Paclitaxels
 acid-sensitive linked PEG conjugates of, 118
 antiproliferative property of, 122
 application of ADEPT method to, 119
 biological actions of, 121–122
 C-11,12 double bond in, 84
 C-13 substituted phenylisoserine side chain and, 76
 “collapsed” conformations of, 109
 fluorescent derivatives of, 95
 immunostimulating effects of, 122
 orally administered, 113
 pharmacophore for, 107, 108–110
 role of 1 β -OH in SAR of, 86
 role of D-ring in, 110
 studies of, 74
 treatment with SmI2, 88
 “T-shaped” (“open”) conformation of, 109
 tubulin binding mechanism of, 106–110
Paclitaxel 7-ethers, 96
Paclitaxel analogs, 92, 111, 112–113, 123
 active against normal tumor cells, 74–106
 with C4-C6 bridge, 100
 conformationally strained, 81
 D-seco, 102
 14 β -OH, 85–86
 9 β -OH, 89
 non-prodrug water-soluble, 119
 with 7 α -F, 96
 synthesis of, 87
Paclitaxel-coated stents, 122
Paclitaxel conformation, differences in, 108
Paclitaxel/epothilone pharmacophore model, 25
Paclitaxel-induced apoptosis, 121
Paclitaxel-mimicking action, of antimicrotubule molecules, 122–123

- Paclitaxel prodrugs, 120–121
 design, synthesis, and pharmacological activity of, 117–121
 disulfide linkage to preparing, 119
- Paclitaxel resistance
 factors contributing to, 115–116
 tubulin mutant and, 116
- Paclitaxel-resistant tumors, 111
- Paclitaxels, 6 α -F, Cl, and Br, 98
- Paclitaxel-selected cell lines, Epothilone activity against, 8
- Paclitaxel-tubulin binding, 107
- PAF receptor antagonists, 309. *See also* Platelet-activating factor (PAF) receptor
- PAF receptor–ginkgolide interaction, characterizing, 311–312
- Palladium-catalyzed coumarin formation reaction, 348–349
- Pancreatic carcinogenesis, sarcophytol A and B, 265
- Parasites, qinghaosu action on, 225
- para*-substituents, 92
- para*-substituted benzamido docetaxel analogs, C-2, 94
- PEG-linked prodrugs, 118
- Peng, Lizeng, 257
- Peptide binding site, D-Ala-D-Ala, 65
- Peptides, interaction with qinghaosu, 235
- Peptidoglycan, 39–40
- Peripheral benzodiazepine (PB) receptors, effect of ginkgolides on, 314–315
- Peripheral blood monocytes (PBMCs), microtubule bundling in, 27
- Peroxy group, in qinghaosu, 206
- PfATP6, 237
- P-gP inhibitor, 113
- P-gp-mediated drug resistance, 7
- P-gPs, structural changes in, 115
- Pharmacokinetics, of ZT-1, 171
- Pharmacological activity, of paclitaxel prodrugs, 117–121
- Pharmacophore modeling, 25–26, 28
- Phase II trials, with BMS-247550, 27
- Phenolic compounds, from *Artemisia annua*, 196
- Photoaffinity labeling experiments, 107, 109
- Photolabeling techniques, 311
- Photooxidation, 202
- Photoreactive probes, 95, 107
- Phytochemistry, of qinghao, 188–197
- Picrotoxin, 313
- Picrotoxinin, 313
- Plant-derived anti-HIV agents, 357–391
- Plasma BuChEs, 150
- Platelet-activating factor (PAF) receptor, ginkgolides and, 301, 308–312. *See also* PAF entries
- Platelet-derived growth factor receptor (PDGF-R), 8
- “Polar” conformation, 109
- Polar epothilone analogs, 24
- Polyacetylene ponticaepoxide, from *Artemisia annua*, 196
- Polyalkene, oxidations of, 416–417
- Poly(L-glutamic acid)-paclitaxel (PG-TXL), 117
- Polyol-carbonate prodrug, of paclitaxel, 117–118
- Position isomers, 368–372
- Prodrugs, 95
 for enhancing specificity, 119–121, 123
 folate-PEG-modified, 120
 to improve water solubility, 117–119
 PEG-linked, 118
 synthesis of, 117–119
- Program 523, 184, 185
- Protaxel, 118
- Protease cleavable paclitaxel prodrugs, 120–121
- Protease inhibitors (PIs), 325
- Proteins, interaction with qinghaosu, 235
- Protopine, 184, 185
- Pseudoannonacin A, 407
- Pseudoplexauric acid methyl ester, 280–281, 285
- Pseudoplexaurol, 280–281
 asymmetric total synthesis of, 284–287
- Pseudoplexaurol conversion, to 14-deoxycrassin, 287
- Pyranicin, 427
 total synthesis of, 428
- Pyrano-3',4' stereoselectivity and modification, 359–362
- Pyrazoline analogs, 113
- Pyrazoline derivatives, 91
- Pyridine-based Epo B analogs, 20
- Pyridine-based epothilone analog, 19
- Qinghao
 genetic engineering of, 206
 history of, 185
 phytochemistry of, 188–197
- Qinghaosu, 183–184, 185. *See also* Artemisinin entries; Qinghaosu derivatives
 acidic degradation of, 199–201
 antimalarial action of, 224–225
 antimalarial activity and the free radical reaction of, 232
 biogenetic synthesis of, 204–206
 biotransformation of, 201–202
 chemical reactions of, 201–202

- chemical synthesis and biosynthesis of, 202–206
- cyclic voltammetry study of, 238
- degradation in alkaline medium, 201
- dimers and trimers of, 219–221
- discovery of, 184–187, 188
- free radical reaction with Fe(II), 225–230
- immunopharmacological action of, 224
- interaction with amino acid, peptides, and proteins, 235–237
- interaction with cysteine, 235–236
- interaction with DNA, 232–235
- interaction with heme, 237
- isotopic-labeled, 206
- lactone of, 198
- 3-methyl-derivatives of, 232
- modification on C-12 of, 207–212
- partial and total synthesis of, 202–204
- pharmacology and chemical biology of, 221–238
- pyrolysis of, 201
- reactions of, 197–202
- reduction of, 198–199
- reduction with sodium borohydride, 199
- structure determination of, 184–187
- Qinghaosu acid, 209
- Qinghaosu analogs, 1,2,4-trioxanes and 1,2,4,5-tetraoxanes as, 221
- Qinghaosu compounds, reaction with ferrous ion, 230
- Qinghaosu derivatives, 183, 206–221
 - antimalarial activity of, 221–222
 - antiparasitic activity of, 222–223
 - antitumor activity of, 223
 - bioactivities of, 221–224
 - containing basic substituent, 214
 - containing the carboxyl group, 213–214
 - immunosuppressive and immunostimulating activities of, 224
 - lipophilic property of, 238
 - steroidal, 218–219
 - treatment with ferrous sulfate, 225
 - water-soluble, 212–214
- Qinghaosu molecule, tandem peroxy, ketal, acetal, and lactone groups in, 198
- Quantitative SAR (QSAR) studies, 358
- (–)-Quinine catalyzed intramolecular oxo-Michael addition (IMA), 343
- total synthesis of (+)-calanolide A using, 343–347
- Quinone-acetogenin hybrids, 435–436
 - inhibitory activity of, 437
- Quinone-mucocin hybrid, 435, 436
- Quinone-squamocin D hybrid, 435, 436
- Racemic calanolide A, structural modifications of, 350
- Racemic calanolides, total synthesis of, 334–338
- Racemic *Calophyllum* coumarins
 - procedure for total synthesis of, 340
 - total synthesis of, 334–340
- Racemic cordatolides, total synthesis of, 339–340
- Racemic HA. *See also* Huperzine A (HA)
 - palladium-catalyzed bicycloannulation route to, 157
 - synthesis of, 154–157
- Racemic HA analogs, 161
- Racemic inophyllum, total synthesis of, 338–339
- Radiolabeled ginkgolides, preparation of, 307
- Reminyl, 144
- Retro-aldol reaction, 94
- Reverse transcriptase (RT). *See* HIV-1 RT;
Nucleoside HIV reverse transcriptase (HIV-RT) inhibitors (NRTIs); Nucleotide RT inhibitor (NtRRTI)
- Ring A, modification of, 379–380
- Ring-closure metathesis (RCM), 103
- Ring closure reactions, synthetic strategy of, 46, 48
- Ring contraction/expansion, C9–C11 region, 10.
See also Ring expansion technique
- Ring-expanded analogs, 13
- Ring expansion technique, 273
- Ring N-atom, position of, 20
- Ring size, alteration of, 372
- Ristocetin-type (type III) glycopeptides, 37, 38
- Ritonavir, 325
- Rivastigmine, 144
- RNA-dependent DNA polymerase (RDDP), 333
- Robustanol, 184, 185
- Rollidecin, total synthesis of, 418
- RPR103611, 384–386
- R/S ratios, 111
- Saguinavir, 325
- Sarcoglaucol, 260
- (+)-Sarcophine, 260
- Sarcophinone, 260
- Sarcophytol A
 - physiological action of, 265–266
 - total synthesis of, 267–268
- (±)-Sarcophytol A, total synthesis of, 268
- Sarcophytol B
 - physiological action of, 265–266
 - total synthesis of, 268–269
- (±)-Sarcophytol M, total synthesis of, 269–271

- Sarcophytols, 258–260
total synthesis of, 267–271
- Sarcophyton*
cembrane-type constituents from, 258–265
sarcophytols from, 258–260
- Sarcophyton birkilandi*, 260
- Sarcophyton glaucum*, 258
- Sarcophytoxide, 260
- (–)-Sarcophytoxide, 262
- SAR results, for 14 β -OH paclitaxel and docetaxel analogs, 85–86. *See also* Structure activity relationship (SAR)
- SAR studies, 358
of DCK and DCP analogs, 373
of epothilone structure, 18
for ginkgolides, 311
of glycopeptide antibiotics, 49–65
systematic, 64
- SB-T-1213, 111
- Schiff base HA derivatives, 162
- Schöllkopf bislactimether synthesis, 45
- Scopolamine, cognitive impairments produced by, 170, 172
- Semisynthetic glycopeptide derivatives, synthesis of, 64
- Semisynthetic taxoids, multidrug resistance, 111–116
- Sesquiterpenes, 188
isolated from *Artemisia annua*, 190–191
isolation of, 189
structures of, 192–194
- 7-esters, bioactivity of, 95
- Sharpless asymmetric epoxidation, 281
- Sharpless hydroxylation/aminohydroxylation, 45
- Side-chain modifications, 381–385
in epothilone structure, 18–22
- Side-chain modified structure, 20
- Simian immunodeficiency virus (SFV), 389
- 6 α -OH paclitaxel, preparation of, 98
- “Smart” prodrugs, 117
- Sodium artesunate, 212
water-soluble, 207
- Soft corals, as a source of cembrane, 257–258
- cis*-Solamin, total synthesis of, 412
- Solid tumors, antitumor activities toward, 73
- Spatial memory disruption, effects of HA on, 149
- Specificity, prodrugs for enhancing, 119–121, 123
- Spindle microtubules, 5
- 10 α -Spiroepoxide, 88
- Squamocin, total synthesis of, 418–419
- Squamotacin, 416
total synthesis of, 417
- Staphylococcus aureus* strains, glycopeptide-resistance of, 42–43. *See also* Methicillin-resistant *Staphylococcus aureus* (MRSA) strains
- Stavudine (d4T), 325
- Steered molecular dynamics (SMD) simulations, 167
- Stents, paclitaxel-coated, 122
- Steric hindrance, 77, 79
- Steroidal qinghaosu derivatives, 218–219
- Steroidal tetraoxanes, 219
- Stigmasterol, 197
- Stille cyclization approach, to (\pm)-isocembrene, 291–295
- Stille sp²-sp² macrocyclization reaction, 295
- Strømgaard, Kristian, 301
- Structure activity relationship (SAR). *See also* SAR entries
of epothilones, 3–4
of Taxol, 74
- Strychnine, 313
- Suksdorfin, as an anti-HIV agent, 358–359
- Sulfur-stabilized carbanion alkylation, 269
- Süssmuth, Roderich D., 35
- Synstab A, 123
- Syntheses. *See also* Biosynthesis; Total synthesis
of cembrene A, 269
of chlorobiphenylbenzyl desleucyl-vancomycin derivatives, 62
of heptapeptides, 65
of huperzine A, 154–166
of nephthenol, 269
of nonproteinogenic amino acids, 45
of optically pure (–)-HA, 157–160
of qinghaosu, 200–201, 202–204
of racemic HA, 154–157
of semisynthetic glycopeptide derivatives, 64
of vancomycin aglycon, 45–47
of vancomycin mimetics, 62
- Synthetic (\pm)-calanolide A, resolution by chiral HPLC, 349
- Synthetic taxoids, with unexpected cytotoxicities, 105
- Systemic lupus erythematosus (SLE), qinghao extraction and qinghaosu in treating, 224
- Tacrine, 144
anti-ChE activities of, 149
- bis*(7)-Tacrine, 168
- Tacrine-TcAChE complex, 168
- Tan, Chang-Heng, 143

- Taxane(s)
7-*O*-glycosylated, 96
synthesis of, 78
tetracyclic core of, 108
with unexpected cytotoxicities, 105
water-soluble, 117
- Taxinine, 114
- Taxoid-epipodophyllotoxin dimers, 104–105
- Taxoids, 78
activity toward MDR tumors, 111–114
A-nor, 83
antitumor effects of, 89
benzoyl, 87
B-ring contracted, 91
14 β -hydroxy and 14 β -acyloxy, 86
macrocyclic, 103, 114
with MDR reversal activities, 114–115
mechanisms of, 124
multidrug resistance and, 111–116
- Taxol, 8, 10
discovery/research and development of, 73–74
incorporation of C-13 side chain into, 74–81
structure activity relationship of, 74
synthesis of, 75
- Taxol-like anticancer drugs, 28
- Taxol-resistant lung carcinoma, 12
- Taxotere, 75
- Taxuspine C, 114
- Taxuspine D, tubulin binding activity of, 106
- TcAChE-ligand complexes, 168
- Teicoplanin aglycones, 55
- Teicoplanins, hybrid, 52
- Teicoplanin-type (type IV) glycopeptides, 37, 38, 40
- Tenofovir, 325
- Terpene trilactones, 303, 304
- Tetracyclic dipyrano-coumarins, 326
- Tetrahydrofuran compounds, 226, 228
- Tetraoxanes, steroidal, 219
1,2,4,5-Tetraoxanes, 221
- bis*-THF acetogenins
activities against human cancer cells, 414–416
mimics for, 429–430
total synthesis of, 413–422
- mono*-THF acetogenins
mimics for, 429–430
total synthesis of, 401–413
- Thin-layer chromatography, chiral selectors used for, 47
- Thio-DCK analogs, 365
- THP-containing acetogenins, total synthesis of, 422–428
3', 4' stereoselectivity, 359–360
3'*R*,4'*R* modification, 360–362
threo-*cis*-*erythro*-*trans*-*threo* configuration, 414
threo-*cis*-*threo* configuration, 412
threo-*trans*-*erythro* configuration, 407
threo-*trans*-*threo*-*trans*-*threo* configuration, 414
- Thyroid carcinoma, 8
- 8-Tigloylated coumarin, 343
- Time-of-addition study, 374
- Titanium-induced intramolecular carbonyl coupling, 274
- Titanium-induced intramolecular coupling, 276
- Titanium-induced macrocyclization, 276
- Titanium-mediated macrocyclization, low-valent, 286
- Tonkinecin
improved synthesis of, 404
total synthesis of, 403–404
- Topoisomerase assays, 105
- Torpedo californica* AChE (TcAChE), interactions of (–)-HA with, 166–167
- Torsional angles, molecular, 365
- Total synthesis. *See also* Asymmetric total synthesis
of cembranolides, 287–290
of cembrene A and C, 271–277
of natural cembranoids, 266–291
of natural epoxy cembranoids, 277–287
of racemic *Calophyllum* coumarins, 334–340
of racemic cordatolides, 339–340
of racemic inophyllum, 338–339
of sarcophytol B, 268–269
of (\pm)-sarcophytol M, 269–271
of sarcophytols, 267–271
of *bis*-THF acetogenins, 413–422
of *mono*-THF acetogenins, 401–413
of THP-containing acetogenins, 422–428
of vancomycin aglycon, 45–47
- Toxicity
of BMS-247550, 27
glutamate, 150–151
- Toxicology
of huperzine A, 152
of ZT-1, 170–171
- Traditional Chinese medicine (TCM)
AChEI originated from, 143–144
modernization of, 184
- Transannular hydride transfer, 82
- Transglycosylases, inhibition by chlorobiphenylbenzyl derivatives, 62
- Transmembrane spanning (TMS) segments, 115–116
- Triazene-phenylglycine derivative, 47
- Tricyclic pyranocoumarins, 326

- Triketocembranoid, 262
- Trilobacin, total synthesis of, 420
- Trilobin, 416
total synthesis of, 417
- Trimer approaches, to glycopeptide design, 58–59
- Trimers, of qinghaosu, 221
- 1,2,4-Trioxanes, 221
- Triterpene betulinic acid derivatives, as anti-HIV agents, 379–390
- Triterpenes, serratene-type, 145
- Triterpenoids, 191
- Trivalent vancomycin-receptor, 60
- 2'-Troc-10-deoxy paclitaxel, 83
- Trp279, 168
- Tryptamine carboxamides, 57
- “T-shaped” conformers, 109, 110
- Tubulin
Taxol binding to, 124
three-dimensional conformation of, 25
- Tubulin binding activity, of Taxuspine D, 106
- Tubulin binding mechanism, of paclitaxel, 106–110
- Tubulin isotype expression, drug-induced alteration of, 116
- Tubulin mutant, paclitaxel resistance and, 116
- Tubulin mutations, 7–8
- Tubulin polymerization, 16, 106–107
in vitro, 23
- “Tubulin polymerization inhibitors,” 2
- Tumor cells, paclitaxel analogs active against, 74–106. *See also* Cancer entries
- Tumor necrosis factor- α (TNF- α), inhibition of, 265
- Tumor necrosis factor (TNF)-like activity, 122
- Tumors, drug-resistant, 111–114. *See also* Cancer entries; MDR tumors; Solid tumors
- 12 β -allyldeoxoartemisinins, 210
- 2 α -N substituted docetaxel analog, synthesis of, 93–94
- Type I–V glycopeptides, 37, 38, 40
- U.S. Food and Drug Administration (FDA), 2
- Uvaricin, 416
total synthesis of, 420
- Vancomycin, 35
alkylation reactions with, 57
binding to the Lys-D-Ala-D-Ala peptide, 41
deglycosylated, 51
dimerization tendency of, 40
glycosylation of, 52
as smallest known ligand-receptor system, 59
- Vancomycin aglycon, total synthesis of, 45–47
- Vancomycin mimetics, synthesis of, 62
- Vancomycin receptor, trivalent, 60
- Vancomycin resistance, 35
- Vancomycin-resistant bacteria, glycopeptides with antibiotic activity against, 59–64
- Vancomycin-resistant enterococci (VRE), 57
- Vancomycin structure, 37–39
stereochemical features of, 39
- Vancomycin-type glycopeptide antibiotics
semisynthetic modifications of, 50
structures of, 36
- Vancomycin-type (Type I) glycopeptides, 37, 38
biosynthesis of, 43
- Vancosamines, *N*-acylation of, 57
- Vancosamine sugar amino groups, derivatization of, 57–58
- vanS gene, 42
- Vascular dementia, huperzine A for treatment of, 151
- Verapamil, 114, 115
- Verbal recall, huperzine A in promoting, 154
- Vincristine (VCR) accumulation, 114
- Wagner–Meerwein rearrangement, 91
- Wang, Lin, 325
- Wang resin, 368
- Water solubility
drug candidate development and, 367–368
of paclitaxel, 117
prodrugs to improve, 117–119
- Water-soluble qinghaosu derivatives, 212–214
- Wu, Yu-Lin, 183, 399
- Yao, Zhu-Jun, 399
- Yingzhaosu, 185
peroxide structure of, 187
- Yingzhaosu A, 184
- Yu, Donglei, 357
- Zalcitabine (ddC), 325
- Zhang, Tao, 257
- Zhu, Da-Yuan, 143
- Zidovudine (AZT), 325
- ZT-1, 169–172
ChE inhibition by, 170
clinical trials of, 172
cognitive enhancement by, 170
pharmacokinetics of, 171
pharmacology of, 170
toxicology investigations of, 170–171
- Zyvox, 65